Downtrend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Jul 7 · below the Ichimoku cloud · RSI 30 (oversold) · MACD above its signal
None of the 29 investors followed here reported a position in LIPO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LIPO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for LIPO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 60.2 | -44.5 | -63.8 | -13.7 | 100.0 | 14.7 | -71.5 | -98.8 | 25.0 | 20.0 | −99.7% | ||
| 2025 | -11.1 | 8.1 | -14.3 | -0.8 | 11.6 | -68.8 | -19.2 | -15.8 | 1.7 | -27.5 | -24.1 | -45.5 | −94.1% |
| 2024 | -2.0 | 4.0 | -34.1 | 6.3 | -11.8 | -29.9 | 89.1 | -50.7 | 12.4 | -18.0 | 0.5 | -1.9 | −62.6% |
| 2023 | -20.9 | -16.4 | -5.8 | 25.1 | -18.0 | 7.0 | -5.1 | -1.5 | -25.0 | -24.7 | 0.0 | -9.7 | −67.4% |
| 2022 | — |
No analyst coverage for this instrument.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.